InferMed Wins Frost and Sullivan Entrepreneurial Company of the Year Award
Posted on: Wednesday, 21 February 2007, 06:00 CST
LONDON, February 21 /PRNewswire/ -- InferMed Ltd, a provider of advanced software solutions for clinical research and practice, has been named the Entrepreneurial Company of the Year at the 2007 Frost and Sullivan awards.
Frost and Sullivan selected InferMed to receive the prestigious award for the Company's demonstration of superior entrepreneurial ability, excellence in decision support, and the significant market potential of its innovative and unique products; MACRO and Arezzo.
InferMed's first product, MACRO, is an Electronic Data Capture (EDC) solution for clinical research, which is currently used in over 36 countries worldwide to collect data from patients in clinical trials and studies. Arezzo, InferMed's second product, is highly advanced clinical decision support software designed to aid clinicians through the process of diagnosis. Arezzo provides clinical guidelines and protocols at the point-of-care, reducing the risk of misdiagnosis and improving treatment for patients.
InferMed was formed in 1999, as a spinout from the Imperial Cancer Research (now Cancer Research UK) Advanced Computational Laboratory, with the mission to commercialise highly advanced software technology developed for clinical research and practice.
Dr Robert Dunlop, Clinical Director for InferMed, said: "Continual advances in medical science are making the practice of medicine increasingly complex and extremely difficult for clinicians to keep up with current best practice. InferMed's mission is to provide the products to help discover the best treatments, and guide clinicians in making sure those treatments get to the patient. We want to help get the right treatment to the right patient at the right time."
Roger Wallhouse, Chairman of InferMed, added: "Since its creation, the company has had a strong entrepreneurial spirit, which has allowed us to become one of the leading companies in the field of electronic data capture, providing innovative, cutting edge products to researchers and clinicians. We are extremely pleased to receive this award, which highlights the hard work and dedication of our staff."
InferMed's products have been used in clinical trials involving more than 85,000 patients worldwide. Current customers include Roche, Siemens, Organon, Cancer Research UK, the Medical Research Council, and the Institute of Cancer Research
About InferMed
InferMed Ltd is a provider of advanced software solutions for clinical research and practice. The Company was founded in 1999, as a spinout from the Imperial Cancer Research (now Cancer Research UK) Advanced Computational Laboratory, with the mission to commercialise highly advanced software technology developed for clinical research and practice. InferMed's products are currently used across healthcare, pharmaceutical and clinical research sectors worldwide
InferMed's lead products, MACRO and Arezzo were developed from work started at Cancer Research UK. MACRO supports clinical trials, helping with the collection of data and the management of trial protocols, and is currently being used for over 85,000 patients at more than 400 sites in 36 countries worldwide. Arezzo is highly advanced clinical decision support software designed to aid clinicians through the process of diagnosis. Arezzo provides active clinical guidelines and protocols at the point-of-care, reducing the risk of misdiagnosis and improving treatment for patients.
Website: http://www.infermed.com/ Contacts at InferMed: Media relations for InferMed: At InferMed: Northbank Communications Roger Wallhouse, Chairman Lorna Watson, Account Director t : +44(0)20-7291-7410 Tony Stephenson, Account Manager e: roger@healthsys.com Katie Odgaard, Account Executive t : +44(0)20-7268-3002 e: infermed@northbankcommunications.com
Frost & Sullivan
CONTACT: Media relations for InferMed: Northbank Communications, LornaWatson, Account Director, Tony Stephenson, Account Manager, Katie Odgaard,Account Executive, t : +44(0)20-7268-3002, e:infermed@northbankcommunications.com; At InferMed: Roger Wallhouse, Chairman,t : +44(0)20-7291-7410, e: roger@healthsys.com
Source: PRNewswire
Related Articles
- Carnegie Mellon Software Engineering Institute to Host 13th Annual International Software Product Line Conference
- Canary Foundation and Stanford University Commit $20 Million for World-Class Research Center for Cancer Early Detection
- Advanced Cancer Therapeutics Appoints Gilles Tapolsky, Ph.D. To Chief Scientific Officer
- New Report Examines Current Use and Future Impact on Global Clinical and Reimbursement Practices
- Randall B. Riggs Joins Advanced Cancer Therapeutics As President & CEO
- IBM's Master Data Management Software Products Are Analyzed and Placed in Two New Gartner Magic Quadrants
- EpiCept Initiates Advanced Cancer Study
- NovaShunt AG, a Medical Device Company Focused on Implantable Fluid Management Systems, Appoints Fiona Sander, MSME, As Director of Research & Clinical Affairs
- Lung Transplantation: Opportunities for Research and Clinical Advancement
- Regeneron's VEGF Trap Demonstrates Positive Preliminary Results From Single-Agent Phase 1 Trial in Patients With Advanced Cancer; Results Presented at ASCO Annual Meeting on May 16, 2005
 |
 |
User Comments (0)
RSS Feeds